[1] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7. doi: 10.3322/caac.21551
[2] GOURD E. Pyrotinib shows activity in metastatic breast cancer[J]. Lancet Oncol, 2017, 18(11): e643. doi: 10.1016/S1470-2045(17)30755-6
[3] BLAIR HA. Pyrotinib: first global approval[J]. Drug, 2018, 78(16): 1751. doi: 10.1007/s40265-018-0997-0
[4] 宋路瑶, 叶国麟, 李巍. 曲妥珠单抗治疗Her-2阳性乳腺癌的最佳时长的研究进展[J]. 重庆医学, 2020, 49(12): 2038. doi: 10.3969/j.issn.1671-8348.2020.12.032
[5] 曹晓珊, 丛斌斌. HER-2阳性乳腺癌靶向药物治疗的研究进展[J]. 中国肿瘤临床, 2019, 46(18): 965. doi: 10.3969/j.issn.1000-8179.2019.18.945
[6] 殷发祥, 钱军. 浸润性乳腺癌及不同分子分型病人的血脂水平分析[J]. 蚌埠医学院学报, 2020, 1(45): 81.
[7] DERAKHSHANI A, REZAEI Z, SAFARPOUR H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy[J]. J Cell Physiol, 2020, 235(4): 3142. doi: 10.1002/jcp.29216
[8] 度敏, 成宏, 周勇, 等. lncRNA-ATB促进乳腺癌细胞侵袭转移及曲妥珠单抗耐药的临床和分子机制研究[J]. 徐州医科大学学报, 2020, 40(12): 870. doi: 10.3969/j.issn.2096-3882.2020.12.003
[9] LIN X, YANG C, WAN H, et al. Discovery and development of pyrotinib: A novel irreversible EGFR/HER-2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer[J]. Eur J Pharm Sci, 2017, 110(12): 51.
[10] 宋国红, 李惠平, 邸立军, 等. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52(2): 254.
[11] JIANG ZF, YAN M, HU XC, et al. Pyrotinib combined with capecitabine in women with HER2+metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(29): 1001.
[12] OEHRLICH NE, SPINELI LM, PAPENDORF F, et al. Clinical outcome of brain metastases differs significantly among breast cancer sub-types[J]. Oncol Lett, 2017, 14(1): 194. doi: 10.3892/ol.2017.6166
[13] RAMAKRISHNA N, TEMIN S, CHANDARLAPATY S, et al. Recommendatio ns on disease management for patients with advanced human epidermal growth factor receptor2 positive breast cancer and brain metastases: ASCO clinical practice guideline update[J]. J Clin Oncol, 2018, 36(27): 2804. doi: 10.1200/JCO.2018.79.2713
[14] MORIKAWA A, STANCHINA E, PENTSOVA E, et al. Phase Ⅰ study of intermittent high dose lapatinib alternating with capecitabine for HER-2 positive breast cancer patients with central nervous system metastases[J]. Clin Cancer Res, 2019, 25(13): 3784. doi: 10.1158/1078-0432.CCR-18-3502
[15] 胡琴, 殷飞, 江萍, 等. 吡咯替尼治疗HER-2阳性晚期乳腺癌患者的近期疗效观察[J]. 肿瘤药学, 2020, 10(4): 472.
[16] MA F, OUYANG QC, LI W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study[J]. J Clin Oncol, 2019, 37(29): 2610.
[17] MA F, LI Q, CHEN S, et al. Phase Ⅰ study and biomarker analysis of pyrotinib, a novel irreversible Pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer[J]. J Clin Oncol, 2017, 35(27): 3105.